Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 3
2006 2
2007 1
2008 1
2009 4
2010 4
2012 3
2013 2
2014 2
2015 6
2016 12
2017 6
2018 4
2019 3
2020 11
2021 2
2022 3
2023 4
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).
Watson CH, Gsell PS, Hall Y, Camacho A, Riveros X, Enwere G, Vicari A, Nadlaou SD, Toure A, Sani IM, Diallo A, Kolie C, Duraffour S, Ifono K, Maomou A, Dore K, Djidonou HA, Bagayoko A, Damey PP, Camara MN, Diallo FB, Oumar FT, Toure K, Diaby ML, Sylla L, Conde D, Kaba IL, Tipton T, Eggo RM, Marks M, Roberts CH, Strecker T, Günther S, Keita S, Edmunds WJ, Carroll MW, Henao-Restrepo AM. Watson CH, et al. Among authors: strecker t. BMC Med. 2024 Nov 7;22(1):523. doi: 10.1186/s12916-024-03726-z. BMC Med. 2024. PMID: 39511527 Free PMC article.
Therefore, we assessed the impact pre-existing immunity had on post-vaccination IgG titre, virus neutralisation, and reactogenicity following vaccination. METHODS: In this prospective cohort study, 2115 consenting close contacts ("proches") of EVD survivors were recruited. …
Therefore, we assessed the impact pre-existing immunity had on post-vaccination IgG titre, virus neutralisation, and reactogenicity f …
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive network.
Hofmann N, Bartkuhn M, Becker S, Biedenkopf N, Böttcher-Friebertshäuser E, Brinkrolf K, Dietzel E, Fehling SK, Goesmann A, Heindl MR, Hoffmann S, Karl N, Maisner A, Mostafa A, Kornecki L, Müller-Kräuter H, Müller-Ruttloff C, Nist A, Pleschka S, Sauerhering L, Stiewe T, Strecker T, Wilhelm J, Wuerth JD, Ziebuhr J, Weber F, Schmitz ML. Hofmann N, et al. Among authors: strecker t. J Virol. 2024 Oct 22;98(10):e0093524. doi: 10.1128/jvi.00935-24. Epub 2024 Sep 16. J Virol. 2024. PMID: 39283124 Free PMC article.
A newly developed open access web application allows downloads and visualizations of all gene expression comparisons for individual viruses over time or between several viruses. Most of the genes included in the core set of commonly differentially expressed genes (D …
A newly developed open access web application allows downloads and visualizations of all gene expression comparisons for individual virus …
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.
Brouwer PJM, Perrett HR, Beaumont T, Nijhuis H, Kruijer S, Burger JA, Bontjer I, Lee WH, Ferguson JA, Schauflinger M, Müller-Kräuter H, Sanders RW, Strecker T, van Gils MJ, Ward AB. Brouwer PJM, et al. Among authors: strecker t. Cell Rep. 2024 Sep 24;43(9):114708. doi: 10.1016/j.celrep.2024.114708. Epub 2024 Sep 6. Cell Rep. 2024. PMID: 39243373 Free PMC article.
The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of vaccines that can elicit strong neutralizing antibody responses. ...By applying this method to rabbits vaccinated with a recombinant GPC vacc …
The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of v …
Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry.
Zhang Z, Takenaga T, Fehling SK, Igarashi M, Hirokawa T, Muramoto Y, Yamauchi K, Onishi C, Nakano M, Urata S, Groseth A, Strecker T, Noda T. Zhang Z, et al. Among authors: strecker t. J Virol. 2024 Jul 23;98(7):e0071424. doi: 10.1128/jvi.00714-24. Epub 2024 May 29. J Virol. 2024. PMID: 38809021 Free PMC article.
Lassa virus (LASV) is the causative agent of human Lassa fever which in severe cases manifests as hemorrhagic fever leading to thousands of deaths annually. ...Through the generation of a HES-resistant virus, we found that phenylalanine at position 446 (F446) within …
Lassa virus (LASV) is the causative agent of human Lassa fever which in severe cases manifests as hemorrhagic fever leading to thousa …
A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies.
Donnellan FR, Rayaprolu V, Rijal P, O'Dowd V, Parvate A, Callaway H, Hariharan C, Parekh D, Hui S, Shaffer K, Avalos RD, Hastie K, Schimanski L, Müller-Kräuter H, Strecker T, Balaram A, Halfmann P, Saphire EO, Lightwood DJ, Townsend AR, Draper SJ. Donnellan FR, et al. Among authors: strecker t. bioRxiv [Preprint]. 2024 Jun 25:2024.06.21.600001. doi: 10.1101/2024.06.21.600001. bioRxiv. 2024. PMID: 38979279 Free PMC article. Preprint.
Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused by Zaire ebolavirus (EBOV). ...
Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caus …
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.
Akoi Boré J, Timothy JWS, Tipton T, Kekoura I, Hall Y, Hood G, Longet S, Fornace K, Lucien MS, Fehling SK, Koivogui BK, Coggins SA, Laing ED, Broder CC, Magassouba NF, Strecker T, Rossman J, Konde K, Carroll MW. Akoi Boré J, et al. Among authors: strecker t. Nat Commun. 2024 May 16;15(1):4171. doi: 10.1038/s41467-024-48587-5. Nat Commun. 2024. PMID: 38755147 Free PMC article.
Human Ebola virus (EBOV) outbreaks caused by persistent EBOV infection raises questions on the role of zoonotic spillover in filovirus epidemiology. ...
Human Ebola virus (EBOV) outbreaks caused by persistent EBOV infection raises questions on the role of zoonotic spillover in filoviru …
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.
Brouwer PJM, Perrett HR, Beaumont T, Nijhuis H, Kruijer S, Burger JA, Lee WH, Müller-Kraüter H, Sanders RW, Strecker T, van Gils MJ, Ward AB. Brouwer PJM, et al. Among authors: strecker t. bioRxiv [Preprint]. 2023 Dec 23:2023.12.21.572918. doi: 10.1101/2023.12.21.572918. bioRxiv. 2023. Update in: Cell Rep. 2024 Sep 24;43(9):114708. doi: 10.1016/j.celrep.2024.114708. PMID: 38187682 Free PMC article. Updated. Preprint.
The isolation of potent and protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of vaccines that can elicit strong neutralizing antibody responses. ...By applying this method to rabbits vaccinated with a recombina …
The isolation of potent and protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the devel …
Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection.
Oestereich L, Müller-Kräuter H, Pallasch E, Strecker T. Oestereich L, et al. Among authors: strecker t. Viruses. 2023 Jun 26;15(7):1436. doi: 10.3390/v15071436. Viruses. 2023. PMID: 37515124 Free PMC article.
BACKGROUND: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. ...Treatment also significantly lowered viremia level and virus load in organs. When treatment was initiated at the o …
BACKGROUND: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are curre …
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Perrett HR, Brouwer PJM, Hurtado J, Newby ML, Liu L, Müller-Kräuter H, Müller Aguirre S, Burger JA, Bouhuijs JH, Gibson G, Messmer T, Schieffelin JS, Antanasijevic A, Boons GJ, Strecker T, Crispin M, Sanders RW, Briney B, Ward AB. Perrett HR, et al. Among authors: strecker t. Cell Rep. 2023 May 30;42(5):112524. doi: 10.1016/j.celrep.2023.112524. Epub 2023 May 18. Cell Rep. 2023. PMID: 37209096 Free PMC article.
Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates viral entry and is the sole target for neutralizing antibodies. ...
Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates vir …
The proprotein convertase SKI-1/S1P is a critical host factor for Nairobi sheep disease virus infectivity.
Bost C, Hartlaub J, Pinho Dos Reis V, Strecker T, Seidah NG, Groschup MH, Diederich S, Fischer K. Bost C, et al. Among authors: strecker t. Virus Res. 2023 May;329:199099. doi: 10.1016/j.virusres.2023.199099. Epub 2023 Mar 22. Virus Res. 2023. PMID: 36948228 Free PMC article.
Nairobi sheep disease virus (NSDV) belongs to the Orthonairovirus genus in the Bunyavirales order and is genetically related to human-pathogenic Crimean-Congo hemorrhagic fever virus (CCHFV). ...Absence of S1P in SRD-12B cells, a clonal CHO-K1 cell variant with a ge …
Nairobi sheep disease virus (NSDV) belongs to the Orthonairovirus genus in the Bunyavirales order and is genetically related to human …
74 results